This report on the organ transplant immunosuppressant drugs market studies the current and future prospects of the global market. Organ transplant immunosuppressant drugs market are prescribed to patients during or after transplant of organs such as kidney, liver, heart, lung and bone marrow. Organ dysfunction caused due to severe injuries, cancer, organ failure and/or genetic disorders necessitate the requirement for organ transplant procedures. Thus, rise in the number of organ transplants across the globe, along with advancements in the immunosuppressant drugs are expected to propel the global organ transplant immunosuppressant drugs market.
The organ transplant immunosuppressant drugs market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global organ transplant immunosuppressant drugs market with respect to the segments based on the type of drug class, transplant, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global intracranial pressure monitors market.
Based on drug class, the organ transplant immunosuppressant drugs market has been segmented into four major categories: calcineurin inhibitors, antiproliferative agents, mTOR inhibotrs, antibodies and steroids. On the basis of transplant type, the market has been categorized into five segments: kidney, bone marrow, liver, heart, lungs, and others (intestinal and multi-visceral organs). The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2019 to 2026, considering 2018 as the base year.
Geographically, the global organ transplant immunosuppressant drugs market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, Australia, Rest of Asia Pacific), Latin America (Brazil, Rest of Latin America) and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2019 to 2026, considering 2018 as the base year. The research study also covers the competitive scenario in these regions.
The report also profiles major players in the global organ transplant immunosuppressant drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AbbVie, Inc., Astellas Pharma, Inc., Bristol?Myers Squibb Company, F. Hoffmann-La Roche Ltd., Genzyme Corporation (Sanofi S.A.), GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. and Veloxis Pharmaceuticals A/S.
The global organ transplant immunosuppressant drugs market is segmented as follows:
Global Organ Transplant Immunosuppressant Drugs, by Drug Class
Global Organ Transplant Immunosuppressant Drugs, by Transplant
Global Organ Transplant Immunosuppressant Drugs, by Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Organ Transplant Immunosuppressant Drugs Market, By Drug Class
7.1. Organ Transplant Immunosuppressant Drugs Market, By Drug Class, 2021-2028
7.1.1. Calcineurin Inhibitors
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Antiproliferative Agents
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. mTOR Inhibitor
7.1.3.1. Market Revenue and Forecast (2016-2028)
7.1.4. Steroids
7.1.4.1. Market Revenue and Forecast (2016-2028)
7.1.5. Antibodies
7.1.5.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Organ Transplant Immunosuppressant Drugs Market, Transplant Type
8.1. Organ Transplant Immunosuppressant Drugs Market, Transplant Type , 2021-2028
8.1.1. Kidney
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. Liver
8.1.2.1. Market Revenue and Forecast (2016-2028)
8.1.3. Heart
8.1.3.1. Market Revenue and Forecast (2016-2028)
8.1.4. Lung
8.1.4.1. Market Revenue and Forecast (2016-2028)
8.1.5. Pancreas
8.1.5.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Organ Transplant Immunosuppressant Drugs Market, Distribution Channel
9.1. Organ Transplant Immunosuppressant Drugs Market, Distribution Channel, 2021-2028
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2016-2028)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2016-2028)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Forecast (2016-2028)
Chapter 10. Global Organ Transplant Immunosuppressant Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.1.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.1.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.1.4.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.1.4.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.1.5.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.1.5.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.2. Europe
10.2.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.2.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.2.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.2.4.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.2.4.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.2.5.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.2.5.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.2.6.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.2.6.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.2.7.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.2.7.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.3. APAC
10.3.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.3.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.3.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.3.4.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.3.4.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.3.5.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.3.5.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.3.6.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.3.6.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.3.7.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.3.7.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.4. MEA
10.4.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.4.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.4.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.4.4.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.4.4.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.4.5.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.4.5.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.4.6.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.4.6.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.4.7.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.4.7.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.5. Latin America
10.5.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.5.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.5.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.5.4.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.5.4.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, By Drug Class (2016-2028)
10.5.5.2. Market Revenue and Forecast, Transplant Type (2016-2028)
10.5.5.3. Market Revenue and Forecast, Distribution Channel (2016-2028)
Chapter 11. Company Profiles
11.1. Astellas Pharma, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Sanofi Genzyme
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Accord Healthcare Ltd.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Novartis AG
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Mylan Laboratories, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Dr. Reddy’s Laboratories Ltd.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. F. Hoffmann-La Roche Ltd.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. GlaxoSmithKline plc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Veloxis Pharmaceuticals A/S
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Bristol-Myers Squibb Company
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers